

NCI CTRP Attachment 3d

NCI CTRP Accrual Portal Workflow and Screen Shots

Step 1: User accesses the NCI Clinical Trials Reporting Program Accrual website at <http://trials.nci.nih.gov> – see screenshot, page 2

Step 2: User enters “Username” and “Password” – see screenshot, page 2


Step 3: User reviews NCI Clinical Trials Reporting Program burden statement – see screenshot, page 3

Step 4: System displays “Search Submitted Clinical Trials” page – see screenshot, pages 4

Step 5: User selects to “Submit Study Subject Accrual Information” and submits subject level accrual information on that trial record – see screenshots, pages 5 – 6

CTRP Login & Home page

Clinical Trials Reporting Program Login



Clinical Trials Reporting Program

→ NIH Login

OR

Username

Password

Remember me

Sign In

[Need help signing in?](#)

Don't have an account? [Sign up](#)

You are accessing a U.S. Government information system, which includes (1) this computer, (2) this computer network, (3) all computers connected to this network, and (4) all devices and storage media attached to this network or to a computer on this network. This information system is provided for U.S. Government-authorized use only. Unauthorized or improper use of this system may result in disciplinary action, as well as civil and criminal penalties. By using this information system, you understand and consent to the following:

You have no reasonable expectation of privacy regarding any communications or data transiting or stored on this information system. At any time, and for any lawful Government purpose, the government may monitor, intercept, record, and search and seize any communication or data transiting or stored on this information system.

Any communication or data transiting or stored on this information system may be disclosed or used for any lawful Government purpose.

CTRP Burden Statement

NCI CLINICAL TRIALS REPORTING PROGRAM (CTRP) SYSTEM

Warning Notice

- This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.
- This system is provided for Government-authorized use only.
- Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.
- Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.
- By using this system, you understand and consent to the following:
 - The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
 - Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.

NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

OMB#:0925-0600 EXP. DATE: 02/28/2026

Public reporting burden for this collection of information is estimated to average thirty (30) minutes for this questionnaire, including the time to review instructions, search existing data sources, gather and maintain the data needed, and complete and review the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a current, valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden to NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0600) Do not return the completed form to this address.

Select Trial to Submit Subject Accrual Information

NATIONAL CANCER INSTITUTE
CTRP ACCRUAL

Accrual Registration

Trial Search 1

NCI Trial ID: NCI-

Show 25

NCI Trial ID ↑ ↓	NCT Trial ID ↑ ↓	Lead Org ID ↑ ↓	Local Trial ID ↑ ↓	Lead Organization ↑ ↓	Official Title ↑ ↓	Action
NCI-					A Phase I/II Study Of Brentuximab	

Show 25

National Cancer Institute
at the National Institutes of Health

NIH...Turning Discovery into Health

Home
Contact us
Disclaimer Policy
Privacy & Security
Accessibility
FOIA

HHS Vulnerability Disclosure
Clinical Trials Reporting Program (CTRP)
U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
USA.gov

Help and Support
ctrp_support@nci.nih.gov



Study Subject 0



Show/Hide

Export

Search All...

Filter Options



NCI: Lead Organization Trial ID Lead Organization Principal Investigator

A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy

Add Study Subject

Delete All

Confirm 0

Show 25



Study Subject ID ↑ ↓	Participating Site ↑ ↓	Study Subject Registration Date ↑ ↓	Study Subject Birthdate ↑ ↓	Study Subject Sex ↑ ↓	Study Subject Race ↑ ↓	Action
----------------------	------------------------	-------------------------------------	-----------------------------	-----------------------	------------------------	--------

No results to display.

Show 25



National Cancer Institute at the National Institutes of Health

NIH...Turning Discovery into Health

Home

Contact us

Disclaimer Policy

Privacy & Security

Accessibility

FOIA

HHS Vulnerability Disclosure

Clinical Trials Reporting Program (CTRP)

U.S. Department of Health and Human Services

National Institutes of Health

National Cancer Institute

USA.gov

Help and Support

ctrp_support@nci.nih.gov

NIH NATIONAL CANCER CENTER ACCRUAL

Accrual Registration

Show/Hide Export

Study Subject

NCI- Lead Organization Trial ID Lead Organization Principal Investigator

A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy

Confirm 0

Show 25

Study Subject ID ↑ ↓ Participating Site ↑ ↓ Study Subject Registration Date ↑ ↓ Study Subject Birthdate ↑ ↓

No results to display.

Show 25

National Cancer Institute at the National Institutes of Health

NIH...Turning Discovery into Health

Home Contact us Disclaimer Policy Privacy & Security Accessibility FOIA

HHS Vulnerability Clinical Trials Rep U.S. Department of National Institutes National Cancer In USA.gov

Add Study Subject

Required fields are marked with an asterisk (*)

Study Subject ID*

Participating Site*

Study Subject Registration Date* mm/dd/yyyy

Study Subject Birth Date mm/yyyy

Study Subject Sex

Study Subject Race

Study Subject Ethnicity

Study Subject Country

Study Subject Disease Terminology

Study Subject Disease

Cancel Save

Add Subject Accrual Information
All Elements Available in Panel